Climbing consensus sales forecasts for 2022 suggest that last year equity analysts brushed off concerns about pricing restraints.
The fastest share price growth in medtech is always recorded by small-caps, but Tandem reached a new extreme last year.
Several large-cap drug stocks registered healthy gains across the third quarter of 2018, signalling investors' growing confidence in biopharma after a disappointing…
Big cap medtech disappoints – but still beats pharma.
GE arrives to the spin-out party fashionably late.